血脂康胶囊联合辛伐他汀的调脂作用及对24 h尿白蛋白排泄量、血浆内皮素-1水平的影响

Effect of Xuezhikang Capsule combined with simvastatin on lipid regulating and excretion of urine albumin and endothelin-1 level in 24 hours

目的研究血脂康胶囊联合辛伐他汀的调脂作用及对24 h尿白蛋白排泄量、血浆内皮素-1水平的影响。方法选择2012年1月—2016年12月在渭南市第一医院进行诊治的高脂血症患者96例,随机分为观察组与对照组,每组各45例。对照组口服辛伐他汀治疗,观察组联合口服血脂康胶囊治疗,两组均治疗3个月。比较两组的临床治疗效果,以及两组治疗前后的24 h尿白蛋白排泄量、血浆内皮素-1水平。结果观察组的有效率为93.75%(45/48),明显高于对照组的77.08%(37/48),差异有统计学意义(P<0.05)。两组治疗后的血脂水平均明显改善,同组治疗前后比较差异有统计学意义(P<0.05),且观察组明显优于对照组,差异有统计学意义(P<0.05)。两组治疗后的24 h尿白蛋白排泄量与治疗前相比无显著差异,两组治疗后的血浆内皮素-1水平明显降低,同组治疗前后比较差异有统计学意义(P<0.05),且观察组明显优于对照组,差异有统计学意义(P<0.05)。结论血脂康胶囊联合辛伐他汀对高脂血症患者具有显著的调脂作用,并可以有效降低血浆内皮素-1水平,提示长期进行调脂治疗可以有效保护血管内皮细胞功能。

Objective To investigate the clinical effect of Xuezhikang Capsule combined with simvastatin on lipid regulating and excretion of urine albumin and endothelin-1 level in 24 hours. Methods Selected 96 cases of patients with hyperlipidemia who were treated in our hospital from January 2012 to December 2016, divided into two groups randomly. The control group was treated with simvastatin, and the observation group was treated with Xuezhikang capsule. The clinical effects of the two groups were compared, and the urinary albumin excretion rate and endothelin-1 level of 24 hours before and after treatment in the two groups were measured. Results After treatment, the effective rate of the observation group was 93.75%（45/48）, significantly higher than that of the control group 77.08%（37/48）（P 0.05）; the blood lipid levels of the two groups were significantly improved（P 0.05）, and the observation group was significantly better than that of the control group（P 0.05）; there was no significant difference in urinary albumin excretion between the two groups after 24 hours treatment; the level of endothelin-1 in the two groups was significantly lower than that in the control group（P 0.05）, and the observation group was significantly better than the control group（P 0.05）. Conclusion Xuezhikang Capsule combined with simvastatin has good lipid-lowering effect on patients with hyperlipidemia, and can effectively reduce the plasmaendothelin-1 level, suggesting that long-term lipid-lowering therapy can effectively protect the function of vascular endothelial cells.